Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool June 15, 2011 Brian Orelli	Johnson & Johnson Is a Quitter The diversified health-care giant has decided to exit the drug-eluting stent market.
The Motley Fool June 4, 2010 Brian Orelli	Out With Drugs, in With Medical Devices Johnson & Johnson's movement in medical devices and diagnostics is headed in the right direction, but whether Johnson & Johnson is a buy depends a lot on how it handles its current drug problem. Unfortunately investors can't have one without the other.
The Motley Fool August 29, 2008 Brian Orelli	Stent Makers Getting Desperate Johnson & Johnson, the first company to bring a drug-eluting stent to the U.S. market, seems like it might be getting a little desperate, as competition increases.
The Motley Fool March 17, 2009 Brian Orelli	Stent Wars, Episode III: The Rise of Xience V Johnson & Johnson lose the lead in the stent war race, but this is a marathon, not a footrace.
The Motley Fool September 30, 2009 Brian Orelli	Boston Scientific Pays Up And Johnson & Johnson reaps the rewards.
The Motley Fool January 23, 2008 Brian Orelli	A Dose of Stability From J&J Top-line growth looked great at Johnson & Johnson -- more than 16% year over year -- but when you dove a little further into the earnings, growth wasn't quite that stellar.
The Motley Fool May 28, 2009 Brian Orelli	Boston Scientific Back in an Atomic Way Can its tiny stent save the day?
The Motley Fool May 20, 2009 Brian Orelli	Johnson & Johnson Tries to Pull a Travolta Johnson & Johnson seems to be making a comeback, after its drug-eluting stent market share fell precipitously to just 15% in the first quarter.
The Motley Fool December 13, 2006 Matthew Crews	Less Support for Drug-Eluting Stents? The FDA responds to a recent controversy. The regulator's stance represents a good-faith-take on the newer stents, which is good news for drug companies.
The Motley Fool May 27, 2010 Brian Orelli	Ever-Evolving Stent Technology (and How to Profit From It) Stay ahead of the curve.
The Motley Fool October 25, 2007 Brian Orelli	Time to Invest in Stents? Stent devices have seen slumping sales over the last few years. Is it time now to invest in the companies that produce them?
The Motley Fool February 5, 2008 Brian Orelli	Medtronic Endeavors to Compete The U.S. drug-eluting stent market just got a little more crowded, after Medtronic announces that the FDA had approved its Endeavor stent for marketing in the U.S.
The Motley Fool March 8, 2005 Stephen D. Simpson	The Stent Wars Continue Although Boston Scientific and Johnson & Johnson have been beating each other silly for market share, recent clinical data suggest little functional difference between drug-coated stents.
The Motley Fool December 17, 2007 Brian Orelli	A Range of Changes for Stent Makers The FDA is about to make it harder for drug-eluting stents to win its approval.
The Motley Fool November 7, 2007 Billy Fisher	SurModics Serves Up a Big Quarter The drug delivery technology company reports record revenue and operating cash flow in its fiscal fourth quarter.
The Motley Fool September 17, 2007 Brian Orelli	Can't See the Trees for the Forest Meta-analysis finds J&J's drug-coated stents are safer than Boston Scientific's stents, maybe. Can J&J use the complex study results to help their falling stent sales?
The Motley Fool October 15, 2008 Brian Orelli	Abbott's Stents Aren't (That) Important Abbott's shareholders shouldn't be too focused on drug-eluting stents.
The Motley Fool July 31, 2007 Nathan Parmelee	Break Out the Band-Aids at J&J Johnson & Johnson is making some deep cuts to change its cost structure. Shareholders haven't had much to cheer about lately here, but the potential benefits from this move could help cure some of the current softness in the business.
BusinessWeek October 31, 2005 Spencer E. Ante	Crashing The Stent Party Conor Medsystems is trying to take on Goliaths J&J and Boston Scientific.
The Motley Fool October 13, 2008 Brian Orelli	Foolish Forecast: J&J's Diversity Counts Views you can use to get clues on tomorrow's news
The Motley Fool January 12, 2007 Billy Fisher	Big Week at Boston Scientific The company's off to a great start so far for 2007. Investors, take note.
The Motley Fool February 2, 2004 Alyce Lomax	Boston Scientific's Stent Hopes Nice quarter, but all eyes should be on the Taxus stent.
The Motley Fool August 6, 2004 Jeff Hwang	Stent Recall Stings Medical device maker Boston Scientific's recall has happened at a crucial time. Will the company lose its market share?
The Motley Fool November 28, 2007 Brian Orelli	Abbott's Future as a Stent Maker The FDA likes Abbott's new drug-eluting stent; it seems likely the advisory committee will recommend that it be approved.
The Motley Fool July 14, 2008 Brian Orelli	Foolish Forecast: J&J Trudges Along In advance of earnings analysts wonder if Johnson & Johnson is a recovery story waiting to happen, or still stuck in a rut?
The Motley Fool April 8, 2005 Stephen D. Simpson	Abbott Hopes to Maxx Out Abbott announced FDA approval to begin a pivotal trial for its drug-eluting stent. Will this be too little too late for shareholders, or a true dark horse?
The Motley Fool July 19, 2005 Stephen D. Simpson	Waiting for Boston Scientific's Second Act The market for drug-coated stents is still lucrative, but BSX needs to deliver on its R&D efforts for long-term success. Investors, take note.
The Motley Fool September 25, 2008 Brian Orelli	Uh-Oh, Stent Makers Drugs are just as good as stents.
The Motley Fool October 12, 2004 Alyce Lomax	Take It Away, J&J Should investors sweat a coming slowdown in growth for pharmaceutical and consumer products giant Johnson & Johnson?
The Motley Fool March 27, 2008 Brian Orelli	Tougher Rules Could Help Stent Makers The FDA has finally issued draft guidance on the minimum requirements that it thinks companies need to fulfill to get drug-eluting stents approved.
Chemistry World March 3, 2015 Phillip Broadwith	J&J to sell cardiac devices to wholesaler Cardinal Johnson & Johnson has agreed to sell its cardiovascular surgical devices subsidiary, Cordis, to wholesale supplier Cardinal Health.
The Motley Fool February 24, 2004 Alyce Lomax	J&J, Guidant Join Forces With intense rivalry looming, is a competitive partnership in vain?
The Motley Fool February 22, 2010 Brian Orelli	So Long, See You in Arbitration After another rejection, Johnson & Johnson and Basilea call it quits.
The Motley Fool February 27, 2008 Brian Orelli	Everyone's Picking on Anemia Drugs A new study in The Journal of the American Medical Association is adding fuel to the fire about Amgen's and Johnson & Johnson's anemia drugs. Should investors worry?
The Motley Fool April 13, 2004 Alyce Lomax	J&J Makes the Day It may be over a hundred years old, but the company reports a spry first quarter.
The Motley Fool December 31, 2009 Brian Orelli	The FDA (Still) Hates Antibiotic Makers Johnson & Johnson and Basilea are the agency's latest victims.
The Motley Fool April 30, 2008 Brian Lawler	Additional Aggravation for Angiotech Could any drugmaker have a worse start to the year?
The Motley Fool April 22, 2010 Brian Orelli	Abbott's Stuck in a Double-Digit Rut The company keeps cranking out solid earnings, but investors don't seem to care.
The Motley Fool May 14, 2008 Brian Orelli	Abbott Knocks Down Boston Scientific Abbott Labs proves its drug-eluting device works better than its competitors as it presented more data from its ongoing Spirit III trial.
The Motley Fool July 14, 2009 Brian Orelli	J&J Eats a Hard Quarter Tough year-over-year comparisons are no match for the health care giant.
BusinessWeek August 8, 2005 Amy Barrett	BW 50: In A Bind Over Stents Safety concerns about drug-coated stents from Johnson & Johnson and Boston Scientific could open the way for rivals.
The Motley Fool February 1, 2005 Stephen D. Simpson	Stent Maker's Hearty Returns Medical device company Boston Scientific rebounds from cardiac stent recall with strong growth.
The Motley Fool May 22, 2009 Brian Orelli	J&J and Cougar: Meow or Roar? Health-care giant Johnson & Johnson is doing something that many of its investors -- Buffett included -- wouldn't do; it's buying a development-stage drugmaker that has no proven drugs.
The Motley Fool April 24, 2007 Ryan Fuhrmann	Boston Scientific Regains Consciousness Recent Boston Scientific results show glimmers of hope. At current prices, the risk/reward tradeoff appears favorable enough to warrant a full checkup on the stock.
The Motley Fool October 19, 2011 Brian Orelli	Not the Best Quarter, but... There's little reason to worry about Johnson & Johnson.
The Motley Fool July 6, 2007 Billy Fisher	Medtronic: For the Broken-Hearted Promising clinical trial could bring a new Medtronic stent to market. Investors, take note.
The Motley Fool December 13, 2006 Stephen Albainy-Jenei	The Latest Standpoint on Stents A panel of experts reaches mixed conclusions on the safety and effectiveness of drug-coated stents. Investors, take note.
The Motley Fool May 28, 2010 Brian Orelli	How Much Is This Going to Cost J&J? Investors need an answer from Johnson & Johnson about low-quality drugs that were recalled. Is the problem systemic, and if so, how much will it cost the company to fix the problem?
The Motley Fool June 23, 2010 Brian Orelli	Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise.
The Motley Fool October 23, 2008 Brian Orelli	Boston Scientific Should Be Thankful The medical device maker's two-year-old acquisition of Guidant has saved it in the third quarter.